Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Pozycja w akcjach #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Cena akcji
$23.57
Ostatnia synchronizacja: 2026-08-20
Kapitalizacja rynkowa
$51.76M
Zmiana (1 dzień)
-0.08%
Zmiana (1 rok)
289.59%
Kraj
US
Handel Apollomics, Inc. (APLM)

Kategoria

EPS dla Apollomics, Inc. (APLM)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Apollomics, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Apollomics, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US